Jpmorgan Chase & CO Biodesix Inc Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$1.2 - $2.13 $523 - $928	436 Added 3963.64%	447 $0
Q3 2023 Nov 14, 2023	BUY	$1.04 - $1.74 $11 - $19	11 New	11 $0
Q2 2022 Aug 11, 2022	SELL	$1.32 - $2.12 $24,134 - $38,762	-18,284 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.69 - $5.81 $52,324 - $179,883	-30,961 Reduced 62.87%	18,284 $31,000
Q4 2021 Feb 10, 2022	BUY	$4.09 - $8.67 $13,034 - $27,631	3,187 Added 6.92%	49,245 $261,000
Q3 2021 Nov 12, 2021	BUY	$6.6 - $12.78 $303,982 - $588,621	46,058 New	46,058 $379,000

62.3M

2.6K

10.1K

Ticker BDSX
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 39,982,000
Market Cap $55.2M
Description
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.